9CSK の概要
| エントリーDOI | 10.2210/pdb9csk/pdb |
| 分子名称 | G1/S-specific cyclin-D1, Cyclin-dependent kinase 4, Atirmociclib, ... (4 entities in total) |
| 機能のキーワード | kinase, inhibitor, cancer, transferase-inhibitor-cell cycle complex, transferase/inhibitor/cell cycle |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 130559.90 |
| 構造登録者 | |
| 主引用文献 | Palmer, C.L.,Boras, B.,Pascual, B.,Li, N.,Li, D.,Garza, S.,Huser, N.,Yuan, J.T.,Cianfrogna, J.A.,Sung, T.,McMillan, E.,Wei, N.,Carmody, J.,Kang, A.N.,Darensburg, S.,Dodd, T.,Oakley, J.V.,Solowiej, J.,Nguyen, L.,Orr, S.T.M.,Chen, P.,Johnson, E.,Yu, X.,Diehl, W.C.,Gallego, G.M.,Jalaie, M.,Ferre, R.A.,Cho-Schultz, S.,Shen, H.,Deal, J.G.,Zhang, Q.,Baffi, T.R.,Xu, M.,Roh, W.,Lapira-Miller, J.,Goudeau, J.,Yu, Y.,Gupta, R.,Kim, K.,Dann, S.G.,Kan, Z.,Kath, J.C.,Nair, S.K.,Miller, N.,Murray, B.W.,Nager, A.R.,Quinlan, C.,Petroski, M.D.,Zhang, C.,Sacaan, A.,VanArsdale, T.,Anders, L. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell, 43:464-481.e14, 2025 Cited by PubMed Abstract: CDK4/6 inhibitors have revolutionized treatment of hormone receptor positive (HR+), HER2 non-amplified (HER2-) breast cancer. Yet, all "dual" CDK4/6 inhibitors show common dose-limiting hematologic toxicities, foremost neutropenia. This poses challenges to provide these agents at concentrations necessary to extinguish cell cycling in tumors. HR+ breast cancer cells are highly dependent on CDK4 but not CDK6. By contrast, CDK4 is dispensable for human bone marrow derived cells, due to the primary and compensatory role of CDK6 in hematopoiesis. This prompted us to develop atirmociclib (PF-07220060), a next-generation CDK4 selective inhibitor. Atirmociclib's impact on circulating neutrophils was reduced, in proportion with its increase in CDK4 versus CDK6 selectivity. Realized dose intensification led to greater CDK4 inhibition and deeper anti-tumor responses, pointing to CDK4 target coverage as a limiting factor of CDK4/6 inhibitor efficacy. We also highlight combinatorial agents that may counter acquired resistance to CDK4 selective inhibition and widen its clinical application. PubMed: 40068598DOI: 10.1016/j.ccell.2025.02.006 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.253 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
をダウンロード
